Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Researchers are collecting detailed biological samples, imaging, environmental data, and patient-reported outcomes from cancer patients to support research aimed at understanding tumor biology and improving cancer care. This observational platform supports multiple projects focusing on different tumor types including thorax, head and neck, breast, gastrointestinal, genitourinary, central nervous system, and rare cancers. The goal is to enhance translational research, biomarker discovery, and clinical cancer study access. Participants provide tumor samples and clinical data which are analyzed using various genetic and molecular profiling techniques such as whole exome sequencing, RNA sequencing, and next-generation sequencing panels. Separate projects include studying young adults with rare cancers, molecular characterization of rare tumors, investigating molecular profiles in relation to environmental radon exposure, and assessing circulating tumor DNA as a marker for cancer recurrence. Participants are involved by providing biological material and clinical information, with data collected on tumor biology and treatment effects over five years. The study measures include understanding tumor biology, disease progression, treatment impact, biomarker identification, and matching patients to biomarker-driven clinical trials. Compliance with follow-up and consent are essential, and the study is designed to improve cancer patient care and research over an extended period.
Actively Recruiting
Researchers are investigating whether adding preoperative chemotherapy to surgery improves the outcomes for patients with high risk retroperitoneal sarcoma, specifically dedifferentiated liposarcoma DDLPS and leiomyosarcoma LMS. This phase III randomized trial compares the effects of surgery alone versus surgery following chemotherapy on disease-free survival in these patients. Participants are assigned to one of two groups the standard treatment group, which undergoes large en-bloc curative-intent surgery within four weeks after randomization, or the experimental group, which receives three cycles of chemotherapy before surgery. Chemotherapy regimens differ by sarcoma type, with high grade LPS patients receiving doxorubicin plus ifosfamide every three weeks, and LMS patients receiving doxorubicin plus dacarbazine every three weeks. Surgery is then scheduled 3 to 6 weeks after the last chemotherapy cycle, with doses adapted per institutional guidelines. During the study, participants undergo imaging assessments to evaluate tumor operability and response to treatment. Researchers monitor disease-free survival over seven years from the first patient enrolled, along with secondary outcomes including overall survival, recurrence, metastasis rates, treatment safety, quality of life, and pathological response. Participants are closely followed through scheduled visits and tests to assess treatment effects and potential complications until study completion in 2028.